A carregar...
Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study
BACKGROUND: The treatment of ulcerative colitis (UC) patients with moderate to severe inflammatory activity with anti-tumor necrosis factor alpha (TNFα) antibodies leads to a clinical remission rate of 10% after 8 weeks of therapy. However, it must be taken into account that patient selection in cli...
Na minha lista:
| Publicado no: | JMIR Res Protoc |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
JMIR Publications
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4942680/ https://ncbi.nlm.nih.gov/pubmed/27352964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2196/resprot.5791 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|